Managers / Q1 2024 · view latest →
Athyrium Capital Management, LP
CIK 0001728001 · 505 FIFTH AVENUE, FLOOR 18, NEW YORK, NY, 10017 · 212-402-6925
Summary
Athyrium Capital Management, LP reported $73M in U.S.-listed holdings across 3 positions for Q1 2024.
The portfolio is heavily concentrated: Omeros alone accounts for 74.3% of reported value.
The book was largely unchanged from Q4 2023.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- US DOMESTIC · 74.3% · $54M
- Other · 16.5% · $12M
- Common Stock · 9.1% · $7M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2023 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| PBYIPUMA BIOTECHNOLOGY INC | TRIMMED | −535.7K | 1.26M | −$1M | $7M |
| Omeros Corp | HELD | +0 | 72.98M | +$8M | $54M |
| Biora Therapeutics Inc. | HELD | +0 | 10.93M | −$3M | $12M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2024
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | Omeros Corp | NOTE 5.250% 2/1 | 74.33% | $54M | 72.98M |
| 2 | Biora Therapeutics Inc. | COM NEW | 16.52% | $12M | 10.93M |
| 3 | PBYIPUMA BIOTECHNOLOGY INChistory → | COM | 9.15% | $7M | 1.26M |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2024 | $9M | 2 | Nov 12, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $34M | 3 | Aug 8, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $73M | 3 | May 16, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $69M | 3 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $114M | 6 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $154M | 7 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $279M | 8 | May 16, 2023 | RESTATEMENT | changes · EDGAR ↗ |
| Q4 2022 | $238M | 11 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $267M | 11 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $238M | 11 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $281M | 10 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $280M | 6 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $158M | 5 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $240M | 5 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $198M | 4 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $208M | 3 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $5M | 1 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $9M | 1 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $98M | 2 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $104M | 3 | Feb 12, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.